Vědecké studie

Real Life Survey

Low pH Hypromellose (Taffix™) nasal powder spray reduced SARS-CoV-2 infection rate post mass-gathering event at a highly endemic community: An observational prospective open label user survey

Klang Shmuel, Mann Barbara , Megiddo Dalia, Lapidot Tair, Napartek Yaakov

Taffix proven highly effective against respiratory viruses

Taffix reduces cell death caused by H1N1 influenza virus by 90%

MDCK cells were treated with H1N1 influenza virus and their viability was tested. Viruses were pretreated by Saline, Taffix and another commercially available product for 5 minutes or 30 minutes prior to infection.

Taffix protects cells from lentivirus infection by 97%

Cell without protection

Fluorescence spots = virus infection in cells,
as seen under microscope

Cell protected with Taffix

Almost no Fluorescence is seen = no virus reached the cells,
as seen under microscope

Fluorescence measurement in cells treated with test solutions. GFP lentivirus was used based on its ability to insert a GFP fluorescent gene into infected cells thus enabling the identification of virus-infected cells.

Taffix completely blocks SARS-CoV-2 (COVID-19 disease) virus cells infection

Efficacy of Taffix against COVID-19 - Plaque assay: virus infectivity

Healthy cells



Cells death after infection by COVID-19 virus

COVID-19 + Taffix

Solution recovered and no virus was detected

Based on this assay, about 4000 virus particles was recovered from the untreated well,
whereas no virus was detected on the gel-treated.

Ten (10) ul of SARS-CoV-2, Hong Kong/VM20, at a clinical disease state concentration of 10^6, was inoculated on to untreated and Taffix gel-treated filters. Taffix amount was equivalent to a clinical dose of 1 puff. The eluting virus solution was tested for RNA level by PCR and for virus infectivity by plaque assay on live cells. The study was performed by Dr. Barbara Mann, Associate Professor, Medicine: Infectious Diseases and International Health, University of Virginia, USA

Efficacy of Taffix against COVID-19 - Quantification of virus RNA - 99.9% blockage

The gel layer produced by Taffix™️ powder after administration of a clinically equivalent amount, effectively blocked SARS-CoV-2 virus, as demonstrated by reduction in virus RNA equivalent to 4 log reduction in virus count. Taffix™️ also protected more than 99% of cells from infection by live SARS-CoV-2 virus.